AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20737495
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg/2 mL IV
Trial: 20737495
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 2 mL IV
Trial: 11333173
Drug: Flecainide (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (low-dose oral)
Trial: 30549145
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (wives on chemotherapy)
Trial: 21205628
Drug: i.v. lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. lidocaine (Group L, n=35)
Trial: 21205628
Drug: i.v. lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. lidocaine (Group L)
Trial: 16533388
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure self-management program for patients with low literacy; education on self-care, daily weight measurement, diuretic dose self-adjustment, symptom recognition, picture-based materials, digital scale, scheduled follow-up.
Trial: 9920082
Drug: Low isoflavone
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low isoflavone diet (64 +/‐ 9.2 mg/day)
Trial: 9920082
Drug: High isoflavone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High isoflavone diet (128 +/‐ 16 mg/day)
Trial: 9920082
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (10 +/‐ 1.1 mg/day)
Trial: 7593708
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of triazolam (0.25 mg)
Trial: 7593708
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of triazolam (0.25 mg)
Trial: 7593708
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of triazolam (0.25 mg)
Trial: 2256974
Drug: Oxpentifylline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxpentifylline 400 mg three times a day for six months
Trial: 24056528
Drug: Emixustat (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emixustat (5, 10, 20, 30, or 40 mg)
Trial: 20459744
Drug: Standard-dose cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclophosphamide, doxorubicin and fluorouracil (CAF)
Trial: 17651679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Crystalens and ReSTOR
Trial: 15716155
Drug: Levodopa (L-dopa)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa (L-dopa) medication
Trial: 15716155
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (off L-dopa)
Trial: 11881867
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml air injection
Trial: 11881867
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml air injection
Trial: 11881867
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml air injection
Trial: 11881867
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml air injection
Trial: 11881867
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml air injection
Trial: 11881867
Drug: ≥4 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥4 ml air injection
Trial: 1672634
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate (1.95 mg)
Trial: 7189485
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg miconazole once daily for 6 days (A)
Trial: 7189485
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg miconazole once daily for 3 days (B)
Trial: 28290274
Drug: Individual tablets
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual tablets
Trial: 24143910
Drug: Multipurpose contact
RxNorm normalized name: CONTACT LENS SOLN (BIOTRUE MULTIPURPOSE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multipurpose contact lens solution/silicone hydrogel lens combination (renu® fresh™ and balafilcon A)
Trial: 23268177
Drug: Hydrodynamic irrigation
RxNorm normalized name: Carbamyl hydroxamate
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrodynamic irrigation with laser root canal therapy (number of patients not specified)
Trial: 23268177
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal treatment (51 patients)
Trial: 19514448
Drug: Vobenzyme added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vobenzyme added to standard antibiotic therapy
Trial: 17623763
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (FAC protocol: 5-fluorouracil, adriamycin, and cyclophosphamide)
Trial: 17623763
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC protocol: adriamycin and cyclophosphamide)
Trial: 17623763
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CMF protocol: cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 17623763
Drug: All chemotherapy
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All chemotherapy protocols
Trial: 1319870
Drug: Crushed tablet
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablet with enteral feeding solution (Osmolite 100 ml/h started 2h before administration and continued for 4h postdose)
Trial: 1319870
Drug: Crushed tablet
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablet without enteral feeding solution
Trial: 1319870
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet (reference)
Trial: 29396806
Drug: Flexion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexion group (knee at 90° flexion for 12 hours, then 60° for 12 hours, combined with 1g TXA topical and 1g TXA intravenous)
Trial: 29396806
Drug: Extension group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension group (knee in full extension, combined with topical and intravenous TXA)
Trial: 29396806
Drug: Controlled group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled group (knee in full extension, combined with single intravenous TXA)
Trial: 19007042
Drug: lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine (150 mg)
Trial: 19007042
Drug: stavudine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stavudine (40 mg)
Trial: 19007042
Drug: nevirapine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nevirapine (200 mg)
Trial: 16614435
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplement with vitamin A
Trial: 12664066
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of lidocaine in the periprostatic nerves
Trial: 10857841
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) adjunctive treatment
Trial: 21422479
Drug: Subantimicrobial-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subantimicrobial-dose doxycycline (SDD)
Trial: 8967667
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) for 12 weeks
Trial: 8967667
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone and Placebo
Trial: 1653773
Drug: BW 91Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW 91Y (3‐deazaadenosine) at 600 pg/ml
Trial: 6142508
Drug: Oral almitrine
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral almitrine 200 mg/day
Trial: 30839430
Drug: Loxoprofen sodium
RxNorm normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen sodium topical patch (LX-P)
Trial: 30839430
Drug: Loxoprofen tablet
RxNorm normalized name: loxoprofen
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen tablet (LX-T)
Trial: 28679073
Drug: Cancer Carers
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer Carers Medicines Management (CCMM)
Trial: 25211703
Drug: Resveratrol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplementation (150 mg)
Trial: 22356705
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of neutral 0.025% sodium fluoride rinse (group II)
Trial: 22356705
Drug: Tooth mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth mousse twice a day in addition to fluoride toothpaste for 6 months (group III)
Trial: 17080442
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) 0.25 mg/kg
Trial: 11829722
Drug: Salvage antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage antiretroviral therapy (specific agents not detailed)
Trial: 11829722
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents and new classes of drugs in salvage therapy
Trial: 9810992
Drug: Silicone occlusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone occlusive gel (Epiderm) used in 61 patients
Trial: 2648927
Drug: Methylprednisolone (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (32 mg)
Trial: 1103271
Drug: Diphenoxylate 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenoxylate 5 mg three times daily
Trial: 8838189
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid complex (ABLC) at 1.2-5.0 mg/(kg.d) for 6 weeks
Trial: 8838189
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AmB) at 0.7-1.2 mg/(kg.d) for 6 weeks
Trial: 28523988
Drug: Myofascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial therapy (8 sessions from 2 to 4 months post-surgery)
Trial: 28523988
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy programme
Trial: 12645187
Drug: Low flow
RxNorm normalized name: high mallow flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow supplemental oxygen therapy
Trial: 9594864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 10) - CPB circuit without treatment
Trial: 7542804
Drug: AZT-3TC combination
RxNorm normalized name: zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZT-3TC combination therapy
Trial: 2466351
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (S)
Trial: 80528
Drug: Cephalothin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin and gentamicin (C.G.)
Trial: 80528
Drug: Methicillin and
RxNorm normalized name: methicillin
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methicillin and gentamicin (M.G.)
Trial: 80528
Drug: Combined cephalothin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cephalothin groups (C.G. and C.T.)
Trial: 80528
Drug: Combined methicillin
RxNorm normalized name: methicillin
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined methicillin groups (M.G. and M.T.)
Trial: 31345981
Drug: Masculinity Barriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masculinity Barriers to Care Scale (MBCS) administered as an online quantitative survey.
Trial: 26951379
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg every 2 weeks)
Trial: 21277394
Drug: Budesonide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (0.25 mg twice daily)
Trial: 19799571
Drug: Interactive Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Voice Response (IVR) system with varying call schedules (weekly, biweekly, monthly)
Trial: 15696287
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of dilute lidocaine (40 mg in 6.0 ml, 3.0 ml for each side or 4.0 and 2.0 ml for two sides)
Trial: 15696287
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (6.0 ml) as a placebo
Trial: 12475460
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE), 0.625 mg
Trial: 12475460
Drug: Transdermal estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol, 0.1 mg/day
Trial: 12475460
Drug: Oral CEE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CEE
Trial: 28910185
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy intervention for smoking cessation over six weeks.
Trial: 23173246
Drug: bushui roumu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bushui roumu recipe (BRR) combined with medroxyprogesterone acetate tablet (MAT)
Trial: 23173246
Drug: artificial period
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial period method (Western medicine group)
Trial: 15975301
Drug: Futalin tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futalin tablets (diclofenac sodium)
Trial: 12474115
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 mg, PO)
Trial: 7751433
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg daily
Trial: 1969172
Drug: Bromazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (3 mg, two daily doses)
Trial: 1969172
Drug: Chlorprothixene (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene (15 mg, two daily doses)
Trial: 351848
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone or prednisolone (30 mg/day)
Trial: 28952191
Drug: Oral lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipid tolerance test (OLTT)
Trial: 21866656
Drug: Routine progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Routine progesterone treatment after laparoscopic surgery
Trial: 19196362
Drug: Multiple drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drugs
Trial: 16924049
Drug: Low-dose acitretin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acitretin (25 mg/d)
Trial: 16924049
Drug: High-dose acitretin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acitretin (50 mg/d)
Trial: 15054734
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (VE) oil solution rinse before and after radiotherapy
Trial: 15054734
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil solution rinse before and after radiotherapy
Trial: 15054734
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (VE) oil solution rinse
Trial: 10443771
Drug: Saccharin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharin (50 mg)
Trial: 8198625
Drug: calcium (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium (800 mg/day) + vitamin D3 placebo
Trial: 30514434
Drug: Visual Schema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual Schema Displacement Therapy (VSDT)
Trial: 28403360
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.23% acidulated phosphate fluoride (APF)
Trial: 23635560
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of paclitaxel, carboplatin, and trastuzumab (12 doses over 16 weeks)
Trial: 23635560
Drug: Every-3-weeks administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-3-weeks administration of paclitaxel, carboplatin, and trastuzumab (4 doses over 12 weeks)
Trial: 23635560
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration in luminal-B (HER2-positive) tumors
Trial: 23635560
Drug: Every-3-weeks administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-3-weeks administration in luminal-B (HER2-positive) tumors
Trial: 23635560
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration in ERBB2+ tumors
Trial: 23635560
Drug: Every-3-weeks administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every-3-weeks administration in ERBB2+ tumors
Trial: 18505646
Drug: Dyract with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyract with prior nonrinse conditioner (NRC) treatment and bonding with Prime&Bond NT
Trial: 18505646
Drug: Polyacid-modified resin
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacid-modified resin composite (F2000) in conjunction with a self-etch adhesive (Prompt-L-Pop, 3M/ESPE)
Trial: 17172172
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with a complex containing Ester-C with antioxidants (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids)
Trial: 11155094
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR (3 injections at 4 week intervals)
Trial: 11155094
Drug: Lanreotide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (5 injections at 14 day intervals)
Trial: 1491345
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of moxisylyte
Trial: 8103112
Drug: Intracavernous administration
RxNorm normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavernous administration of moxisylyte
Trial: 3756776
Drug: Chemotherapy (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cyclophosphamide, vincristine, and prednisone [CVP], five courses)
Trial: 29390245
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron therapy with sodium ferrigluconate
Trial: 26903081
Drug: Mind-body program
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body program (8-week group program followed by 6 monthly sessions)
Trial: 23377510
Drug: Dapsone 5%
RxNorm normalized name: DAPSONE 5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 5% gel
Trial: 15593011
Drug: 2-dose IPT
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose IPT with SP